




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>A61K 9/70</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/38659</b> <b>(43) International Publication Date:</b> 6 July 2000 (06.07.00)
<b>(21) International Application Number:</b> PCT/GB99/03811 <b>(22) International Filing Date:</b> 17 November 1999 (17.11.99) <b>(30) Priority Data:</b> 9828480.5                      24 December 1998 (24.12.98)      GB <b>(71) Applicant (for all designated States except US):</b> DERMATECH LIMITED [GB/GB]; Kramer Mews, London SW5 9JL (GB). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> SOLOMON, Montague, Cecil [GB/GB]; 19 St. Leonard's Terrace, London SW3 4QT (GB). TOCILI, Biljana [MK/GB]; 4a Ackmar Road, London SW6 4OP (GB). SOLOMON, David, Louis, Charles [GB/GB]; 84a Philbeach Gardens, London SW5 (GB). <b>(74) Agent:</b> SERJEANTS; 25 The Crescent, King Street, Leicester LE1 6RX (GB).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DE (Utility model), DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> TRANSDERMAL DRUG DELIVERY SYSTEM  <div style="text-align: center;">  </div> <b>(57) Abstract</b> <p>In a method of manufacturing such a system, an active substance is dissolved in a ratio less than saturation level in a solvent which is also a skin penetration enhancer. The system (4) is coated as a layer onto a siliconized release paper (2) and laminated onto a backing strip (6).</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

TITLE

Transdermal Drug Delivery Systems

DESCRIPTIONTechnical Field

The invention relates to transdermal drug delivery systems, that is systems for the administration of medicine through the skin of a patient and into the systemic circulation. In this way, the medicine avoids passing through the gastro-intestinal tract and liver. Thus metabolism is to some extent avoided, and a smaller dose can be used.

Background Art

GB 2249956 contains a useful summary of the state of the art, and discloses such systems containing super-saturated solutions of an active ingredient within an adhesive layer by use of a carefully selected mixture of solvents.

THE INVENTION

The invention provides a method of manufacturing a transdermal drug delivery system which comprises dissolving a pharmaceutically active substance in a ratio less than saturation level in a solvent which is also a skin penetration enhancer, and mixing the resulting solution with an adhesive in the form of an aqueous dispersion or solution. By using the active substance in a ratio less than saturation level, there is a reduced risk of crystallization, a stable system can be manufactured, and a constant rate of delivery to the patient obtained.

It is surprising that certain solvents act both as a skin penetration enhancer and as a solvent for the active substance. Such solvents include crotamiton, diethyltoluamide (DEET) and mixtures of two or more thereof. The ratio of crotamiton to diethyltoluamide in such a solvent mixture may be from 5:95 to 95:5% by weight of the total enhancer/solvent content depending on the delivery rate and extent of delivery required for the active substance. By choosing a solvent or solvents having a boiling point higher than any drying temperature applied to the system, and controlling the drying temperature, the solvent(s) do not evaporate, the solution of the active substance never becomes saturated, and a high proportion of active substance remains in the

system. The active substance/solvent(s) solution can be maintained at 20°-30°C for over one month.

The system is generally presented on a backing sheet and protected up to use by a release liner.

The pharmaceutically active substance may be:

$\alpha$ -Adrenergic agonists such as Adrafinil, Adrenolone, Amidephrine, Aproclonidine, Clonidine, Ephedrine, Naphasoline and Tramazoline;

$\beta$ -Adrenergic agonists such as Albuterol, Clenbuterol, Clorprenaline, Methoxyphenamine and Terbuterol;

$\alpha$ -Adrenergic blockers such as Amosulalol, Dapiprasol, Ergoloid Mesylates, Prazosin, Terazosin, Yohimbine;

$\beta$ -Adrenergic blockers such as Acebutolol, Alprenolol, Atenolol, Pindolol, Propanolol and Timolol;

Anabolics such as Androstenediol, Ethylstrenol, Methandriol, Nandrolone, Oxymesterone, Quinbolone and Stenbolone;

Analgesic (narcotic) such as Alfentanil, Benzylmorphine, Buprenorphine, Codeine, Codeine Phosphate, Dihydrocodeine, Dihydromorphine, Fentanyl, Methadone Hydrochloride, Morphine, Morphine Derivatives, Narceine, Opium, Oxycodone, Oxymorphone, Phenazocine and Sufentanil;

Analgesics (non-narcotic) such as Acetaminophen, Acetanilide, Acetylsalicylic Acid, Carbamazepine, Diflunisal, Indomethacin, Ketoprofen, Naproxen, Phenacetin, Salicylamide and Tramadol;

Androgens such as Mesterolone, 17-Methyltestosterone, Testosterone and Testosterone Propionate;

Anaesthetics such as Amylocaine Hydrochloride, Bupivacaine, Lidocaine, Midazolam, Procaine, Tetracaine Hydrochloride, Thiopental Sodium and Zolamine;

Anti-acne drugs such as Algestone Acetophenide, Benzoyl Peroxide, Cyproterone, Resorcinol, Retinoic Acid and Tetroquinolone;

Anti-amebic such as Chloroquine, Chlortetracycline, Dehydroemetine, Emetine, Teclosan, Thiocarbamazine and Tinidazole;

Antianginals such as Alprenolol, Amlodipin, Diltiazem, Felodipine, Isosorbide Dinitrate, Nicardipine, Nifedipine, Nitroglycerin, Oxprenolol, Pindolol, Timolol and Verapamil;

Antibacterial drugs such as Gentamicin, Kanamycin, Neomycin, Chloramphenicol, Chloramphenicol Pantothenate, Clindamycin, Lincomycin, Clarithromycin, Erythromycin and Cycloserine;

Anti-estrogens such as Delmadinone Acetate, Tamoxifen and Toremifene;

Antifungal drugs such as Clotrimazole, Econazole, Ketoconazole, Miconazole and Potassium Iodide;

Antihistamines such as Chlorpheniramine, Dimethindene, Pheniramine, Triprolidine and Phenothiazine;

Antihypertensive drugs such as Captopril, Enalapril, Clonidine and Minoxidil;

Anti-inflammatory drugs such as Mefenamic Acid, Flubiprofen, Ibuprofen, Indomethacin, Ketoprofen, Aspirin, Mesalamine, Olsalazine, Piroxicam and Tenoxicam;

Anti-parkinsonian drugs such as Amantadine, Levodopa, Pergolide and Pridinol;

Antipyretics such as Camphor, Menthol, Phenol, Polidocanol, Spirit of Camphor and Trimeprazine;

Anti-seborrheic drugs such as Pyrithione, Resorcinol, Selenium Sulphides and Tioxolone;

Antiseptics such as Chlorhexidine, Bismuth Iodide Oxide, Povidone Iodine, Triclosan, Triclosane Potassium, Carvacrol, p-Cresol, Chloroxine, Halquinol, Boric Acid,  $\alpha$ -Terpineol and Chlorhexidine;

Anti-ulcerative drugs such as Cimetidine, Enprostil, Omeprazol, Ranitidine and Trimoprostil;

Anxiolytic drugs such as Buspirone, Bromazepam, Diazepam, Loxapine, and Meprobamate;

Cholinergic agents such as Bethanechol Chloride, Physostigmine and Pyridostigmine Bromide;

Depigmentors such as Hydroquinine, Hydroquinone and Monobenzone;

Estrogens such as Benzestrol, Dienestrol, Diethylstilbestrol, Dimestrol, Methestrol, Conjugated estrogenic Hormones, Equilenin, Equilin, Estradiol, Estradiol Benzoate, Estradiol 17 $\beta$ -Cypionate, Estriol, Estrone, Ethinyl Estradiol, Mestranol, Moxestrol, Quinestradiol and Quinestrol;

Gonadotropic hormones such as LH and PMSG;

Nootropic agents such as Aceglutamide, Antiracetam, Piracetam, Pyritinol and Tacrine.

Progestogens such as Allylestrenol, Anagestone, Chlormadinone Acetate, Delmadinone Acetate, Demegestone, Desogestrel, Dimethisterone,

Dydrogesterone, Ethisterone, Ethynodiol, Flurogestone Acetate, Gestodene, Gestodene Caprolate, Haloprogestosterone, 17-Hydroxy-16-methylene-progesterone, 17 $\alpha$ -Hydroxyprogesterone, 17- $\alpha$ -Hydroxygesterone Caprolate, Lynestrenol, Medrogestone, Medroxyprogesterone, Megestrol Acetate, Melengestrol, Norethisterone, Norethisterone Acetate, Noretynodrel, Norgesterone, Norgestimate, Norgestrel, Norgestrienone, Norvinistyerone, Pentagestrone, Progesterone, Promegestone, Quingestrone and Trengestone; Respiratory stimulants such as Almitrine, Doxapram, Lobeline, Sodium Succinate and Tacrine; Vitamins, vitamin sources and vitamin extracts such as Vitamins A, B, C, D, E and K and derivatives thereof, Calciferols, Glycyrrhiza and Mecobalamin; or Vulnerary agents such as Acetylcysteine, Allantoin, Asiaticoside, Cadexomer Iodine, Chitin, Dextranomer and Oxaceprol.

The solvent can be Crotamiton, Diethyltoluamide (DEET), Transcutol (Diethylene glycol monoethyl ether), Labrafil MI944CS (unsaturated polyglycolysed glycerides), Labrasol (Glyceryl and polyethylene glycol esters), Tea-tree oil (Oil of Melaleuca), Propylene Glycol, MP DIOL (2-Methyl-1,3- Propanediol) or Polyetheylen Glycol.

It will be appreciated that the amount of active substance to be incorporated in the delivery system is dependent or governed by the drug composition and/or concentration, the desired therapeutic effect for a patient, and the period for which the delivery system is to provide a therapeutic drug level. Preferably, the active substance is present in an amount from 0.1% to 50% by weight of the coating material (i.e. an aqueous emulsion or adhesive solution). More preferably, 0.3% to 30% by weight of the coating material.

The adhesive can be an acrylate, silicone or polyisobutylene. The active substance is generally incorporated in the solvent/enhancer at room temperature (25°C or below) and in a ratio less than 90% of saturation level to prevent crystal formation during storage. Dissolution may be aided by sonication or warming. The resulting solution can be added slowly to the adhesive which may be in the form of an aqueous dispersion or solution, and mixed. An adhesive thickener may be added

to the mixture at about a 50% solution/water mix to produce a thicker spreading solution for reverse roll coating or knife over roll coating.

The resulting delivery system may then be coated onto a release liner, which may be a siliconised polyester such as type FL 2000 (commercially available), or paper, which naturally is impermeable to the active substance. The system can then be dried by circulating hot air, and laminated onto a backing sheet, which may be a 3M Health Care Type 1220, the backing sheet naturally being impermeable to the active substance. The layer may be coated to a wet-coat thickness of from 20 to 500 $\mu$ . Alternatively, the delivery system mixture may be spread or coated onto the backing sheet, and then laminated to the release liner. The hot air circulation may be effected at gradually increased temperatures from 50°C to 140°C.

#### DRAWING

Fig. 1 is section through an adhesive tape for application to the skin of a patient comprising a drug delivery system according to the invention. A delivery system comprising an active substance, adhesive and solvent/skin penetration enhancer 4 is coated as a layer onto a siliconized release paper 2 and laminated onto a backing strip 6.

The following Examples of ingredients in parts by weight may be used in the production of delivery systems as described above:

- 6 -

	<u>Eg 1</u>	<u>Eg 2</u>	<u>Eg 3</u>	<u>Eg 4</u>	<u>Eg 5</u>
Esterol Hemihydrate	1.0	1.0	1.0	1.0	0.9
Norethisterone Acetate	2.0	2.4	2.4	2.4	2.4
DEET	-	-	-	18.0	15.3
Crotamiton	-	18.0	20.0	-	2.7
Labrafil M (1944CS)	5.0	4.25	-	-	-
Transcutol	20.0	-	-	-	-
Lauroglycol	4.0	-	-	-	-
Labrasol	4.0	-	-	-	-
Monsanto 3011	64.00	74.35	-	-	-
Monsanto 2484			76.6	78.6	-
Monsanto 2397	-	-	-	-	-
C945/127		-	-	-	78.7
NS 2287	-	-	-	-	-
Acrysol ASE60	-	-	-	-	-
Ammonia BP (aq.dil)	qs	qs	qs	qs	-
Purified water (BP)	qs	qs	qs	qs	qs



- 7 -

	<u>Eg 6</u>	<u>Eg 7</u>	<u>Eg 8</u>	<u>Eg 9</u>	<u>Eg 10</u>	<u>Eg 11</u>
Estradiol Hemihydrate	0.9	0.9	0.9	1.2	1.1	1.0
Norethisterone Acetate	2.4	2.4	2.4	-	-	-
DEET	9.0	2.7	15.3	-	6.0	6.09
Crotamiton	9.0	15.3	2.7	7.5	0.6	-
Labrafil M(1944CS)	-	-	-	2.0	-	-
Transcutol	-	-	-	-	-	-
Lauroglycol	-	-	-	-	-	-
Labrasol	-	-	-	-	-	-
Monsanto 3011	-	-	-	-	-	-
Monsanto 2484	-	-	-	-	-	-
Monsanto 2397	-	-	-	89.3	-	-
C945/127	78.7	78.7		-	-	93.77
NS 2287	-	-	78.7	-	92.3	-
Acrysol ASE60	-	-	-	-	-	0.2-0.9
Ammonia BP (aq.dil)	-	-	-	-	-	qs
Purified water (BP)	qs	qs	qs	qs	qs	qs

#### Manufacturing Method (illustrative)

##### A) Delivery System using adhesive - aqueous emulsion

The active substance is dissolved in the solvent by means of heating and mixing over a 45°-55°C water bath with agitation. When the solution is optically clear, it is checked microscopically for absence of crystals.

The adhesive is weighed into a separate mixing vessel, diluted with water if necessary over a period not exceeding 30 mins to achieve the requisite viscosity. The active substance/solvent solution is gradually added to the adhesive solution with mixing. The pH is adjusted to 6.5-7.5 and a thickener is added (if appropriate) to obtain a suitable viscosity (eg 900-100 cps) for the selected coating process such as reverse roll coating or knife over roll coating.

The resultant aqueous emulsion is coated onto a release liner (typical coating thickness 20-500  $\mu$ ), and dried by passing in sequence through ovens at 50-140°C. The product is then laminated onto a backing sheet.

**B) Delivery system using an adhesive solution**

The active substance is dissolved in a solvent by means of heating and mixing as described above. The adhesive is weighed in a separate vessel and the active substance/solvent solution is gradually added to the solution of adhesive with mixing. The resultant adhesive solution is coated onto a release liner, dried by passing in sequence through ovens at 50-140°C. The product is then laminated onto a backing sheet.

In-vitro drug delivery through the skin

In-vitro skin permeation experiments with human skin have been on systems made from the above ingredients carried out using Franz-type diffusion cells, and the studies were carried out on a Hanson Microette system.

Dermatomed human skin sections were mounted onto the Franz cells and transdermal drug delivery systems mounted on tape backings (1.5cm<sup>2</sup>) were placed on the stratum corneal surface of the skin. Each Franz cell contained 7ml of ethanol phosphate buffered saline as the receptor medium, maintained at 32°C. At predetermined time intervals 0.7ml of the receptor solution was sampled and an equal amount replaced.

The samples were analysed by High Pressure Liquid Chromatography.

The skin mass transport of Estradiol and Norethisterone Acetate has been found to be enhanced by the solvent/skin penetration enhancer DEET and/or Crotamiton in a concentration below saturation. Further, the active substance flux profile follows the solvent flux profile, the latter showing high skin penetration flux during the first 20 hours of application.

Indications

The main indications are in both peri-menopausal and menopausal women for the control in the former of the symptoms of the menopause such as hot flushes, sweating and the other symptoms of the peri-menopause,


and in the case of the menopause the prevention of osteoporosis and cardiac events such as coronary thrombosis.

**CLAIMS**

1. A method of manufacturing a transdermal drug delivery system which comprises dissolving a pharmaceutically active substance in a ratio less than saturation level in a solvent which is also a skin penetration enhancer, and mixing the resulting solution with an adhesive in the form of an aqueous dispersion or solution.
2. A method according to claim 1 in which the solvent/enhancer includes crotamiton.
3. A method according to claim 1 or claim 2 in which the solvent includes DEET.
4. A method according to any preceding claim in which the active substance includes estradiol.
5. A transdermal drug delivery system manufactured by a method according to any preceding claim.
6. A transdermal drug delivery system according to claim 5 in which the active substance is present in said aqueous dispersion or solution from 0.1% to 50% by weight.

1/1

FIG. 1.



## INTERNATIONAL SEARCH REPORT

International Application No.

P. 99/03811

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 A61K9/70

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 276 561 A (PFIZER INC.) 3 August 1988 (1988-08-03) page 2, line 1 - line 5 page 3, line 5 - line 11 page 3, line 25 - line 51 page 5; example 2	1,2,5,6
Y	WO 92 05811 A (ETHICAL PHARMACEUTICALS LIMITED) 16 April 1992 (1992-04-16) the whole document & GB 2 249 956 A cited in the application	1-6
Y	WO 92 10231 A (THERATECH, INC.) 25 June 1992 (1992-06-25) page 2, line 1 - line 9 page 23 -page 27; examples 6-8	1-6
	-/-	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

28 February 2000

Date of mailing of the international search report

06/03/2000

Name and mailing address of the ISA

European Patent Office, P.B. 6818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Benz, K

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/GB 99/03811

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 569 338 A (GIAPHARMA SA) 10 November 1993 (1993-11-10) page 2, line 56 -page 3, line 39	1,4,6
A	EP 0 483 370 A (HISAMITSU PHARMACEUTICAL CO. INC.) 6 May 1992 (1992-05-06) page 3, line 24 - line 27	2,4
A	WO 98 09591 A (THERATECH, INC.) 12 March 1998 (1998-03-12) page 22 -page 24; examples 6,7	1-6

## INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No.

PCT/IB 99/03811

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 276561 A	03-08-1988	JP 2107853 C	06-11-1996
		JP 7094394 B	11-10-1995
		JP 63159318 A	02-07-1988
		AU 585739 B	22-06-1989
		AU 8297387 A	30-06-1988
		DD 266506 A	05-04-1989
		DK 683987 A	25-06-1988
		EG 18328 A	30-10-1992
		FI 875703 A	25-06-1988
		HU 45894 A, B	28-09-1988
		IL 84860 A	16-02-1992
		KR 9005854 B	13-08-1990
		NO 875419 A	27-06-1988
		NZ 223056 A	28-11-1989
		PH 23817 A	23-11-1989
		PL 269636 A	13-10-1988
		PT 86437 A, B	01-01-1988
		ZA 8709645 A	30-08-1989
WO 9205811 A	16-04-1992	AT 137979 T	15-06-1996
		AU 649732 B	02-06-1994
		AU 8629591 A	28-04-1992
		CA 2093321 A, C	06-04-1992
		DE 69119598 D	20-06-1996
		DE 69119598 T	12-09-1996
		DK 551349 T	30-09-1996
		EP 0551349 A	21-07-1993
		ES 2090355 T	16-10-1996
		GB 2249956 A, B	27-05-1992
		GR 3019929 T	31-08-1996
		JP 2543457 B	16-10-1996
		JP 6501932 T	03-03-1994
		NO 302400 B	02-03-1998
		NZ 240091 A	25-06-1993
		US 5352457 A	04-10-1994
		ZA 9107959 A	30-12-1992
WO 9210231 A	25-06-1992	US 5164190 A	17-11-1992
		US 5152997 A	06-10-1992
		AU 651165 B	14-07-1994
		AU 9175791 A	08-07-1992
		CA 2098195 A, C	11-06-1992
		EP 0562041 A	29-09-1993
		JP 6503252 T	14-04-1994
		PT 99751 A, B	31-01-1992
EP 569338 A	10-11-1993	ZA 9109761 A	28-10-1992
		US 5665377 A	09-09-1997
		AT 169213 T	15-08-1998
		AU 670273 B	11-07-1996
		AU 3845993 A	11-11-1993
		CA 2095789 A	09-11-1993
		DE 69320096 D	10-09-1998
		DE 69320096 T	10-12-1998
		ES 2121975 T	16-12-1998
		JP 2960832 B	12-10-1999
		JP 6014986 A	25-01-1994
		NZ 247549 A	21-12-1997



# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 99/03811

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 569338 A		ZA 9303180 A	14-06-1994
EP 483370 A	06-05-1992	DE 69108512 D	04-05-1995
		DE 69108512 T	03-08-1995
		AT 120368 T	15-04-1995
		AU 633733 B	04-02-1993
		AU 7780091 A	10-12-1991
		CA 2066249 A,C	18-11-1991
		WO 9117752 A	28-11-1991
		JP 2844262 B	06-01-1999
		US 5248676 A	28-09-1993
WO 9809591 A	12-03-1998	US 5985317 A	16-11-1999
		AU 4242797 A	26-03-1998
		BR 9712806 A	23-11-1999
		EP 0952799 A	03-11-1999